Revolution Medicines, Inc.
RVMD
55 insider filings · Latest: Sep 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Jun 26 8:10 PM | Jack AndersChief Financial Officer | Sale | 20,000 | $168.33 | $3.4M | 123,269(D) | View → |
| Jun 24, 2026 | Jun 24 8:35 PM | JACK ANDERS | Proposed Sale | 20,000 | $169.51 | $3.4M | — | View → |
| Jun 16, 2026 | Jun 18 8:11 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 4,615 | $156.12 | $720.5K | 49,975(D) | View → |
| Jun 16, 2026 | Jun 18 8:11 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 10,020 | $156.12 | $1.6M | 267,330(D) | View → |
| Jun 16, 2026 | Jun 18 8:10 PM | Jeff CisliniGeneral Counsel | Sale | 2,157 | $156.12 | $336.7K | 56,521(D) | View → |
| Jun 16, 2026 | Jun 18 8:10 PM | Jack AndersChief Financial Officer | Sale | 2,722 | $156.12 | $425.0K | 123,269(D) | View → |
| Jun 16, 2026 | Jun 18 8:10 PM | Stephen Michael KelseyPresident, Research and Development | Sale | 4,175 | $156.12 | $651.8K | 291,876(D) | View → |
| Jun 17, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Sale | 29,600 | $160.12 | $4.7M | 154,647(D) | View → |
| Jun 15, 2026 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Sale | 60,400 | $160.17 | $9.7M | 158,222(D) | View → |
| Jun 16, 2025 | Jun 17 11:51 PM | Margaret A HornChief Operating Officer | Sale | 3,575 | $156.12 | $558.1K | 154,647(D) | View → |
| Jun 15, 2026 | Jun 15 10:30 PM | GOLDSMITH MARK A | Proposed Sale | 9,772 | $153.87 | $1.5M | — | View → |
| Jun 15, 2026 | Jun 15 10:23 PM | Cislini Jeff | Proposed Sale | 1,656 | $153.87 | $254.8K | — | View → |
| Jun 15, 2026 | Jun 15 10:15 PM | Anders Jack | Proposed Sale | 2,653 | $153.87 | $408.2K | — | View → |
| Jun 15, 2026 | Jun 15 10:07 PM | Mancini Anthony | Proposed Sale | 4,211 | $153.87 | $647.9K | — | View → |
| Jun 15, 2026 | Jun 15 9:59 PM | Kelsey Stephen Michael | Proposed Sale | 4,071 | $153.87 | $626.4K | — | View → |
| Jun 15, 2026 | Jun 15 9:51 PM | Horn Margaret A | Proposed Sale | 3,486 | $153.87 | $536.4K | — | View → |
| Jun 15, 2026 | Jun 15 8:59 PM | MARGARET A HORN | Proposed Sale | 90,000 | $153.87 | $13.8M | — | View → |
| Jun 11, 2026 | Jun 15 8:05 PM | Margaret A HornChief Operating Officer | Sale | 10,000 | $148.01 | $1.5M | 158,222(D) | View → |
| Jun 11, 2026 | Jun 11 8:28 PM | MARGARET A HORN | Proposed Sale | 10,000 | $144.19 | $1.4M | — | View → |
| May 26, 2026 | May 28 8:10 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 3,121 | $153.99 | $480.6K | 54,400(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Grant/Award | 128,600 | $102.02 | 128,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Margaret A HornChief Operating Officer | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Jeff CisliniGeneral Counsel | Grant/Award | 32,500 | $102.02 | 32,500(D) | View → |
| Mar 1, 2026 | Mar 4 2:07 AM | Jack AndersChief Financial Officer | Grant/Award | 45,400 | $102.02 | 45,400(D) | View → |
| Feb 6, 2026 | Feb 10 10:30 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 24,010 | $0.54 | 144,493(D) | View → |
← Previous
Page 2 of 2